Ségolène Martin (@segozone) 's Twitter Profile
Ségolène Martin

@segozone

CEO of techbio company @kantify - AI against rare diseases and cancer

ID: 458741183

linkhttps://be.linkedin.com/in/segolenemartin calendar_today08-01-2012 22:11:19

1,1K Tweet

1,1K Followers

1,1K Following

Kantify (@kantify) 's Twitter Profile Photo

Today, we're unveiling the latest small molecule drug screened by our AI, Sapian. Many of you are familiar with this medication-it was the 169th most prescribed drug in the United States in 2022, with over 3 million prescriptions. This widely used drug is Diazepam, aka Valium.

Ségolène Martin (@segozone) 's Twitter Profile Photo

Huge randomized trial of AI boosts discovery “Teams that were randomly assigned to use the tool discovered 44% more new materials and filed 39% more patent applications than did the ones that stuck to their standard workflow” nature.com/articles/d4158…

Oded Rechavi (@odedrechavi) 's Twitter Profile Photo

Scared to share this after 10 freaking years of waiting but here we go: We found that temperature *perception* can change the next generations, even when “it’s just in the parents' head”. Read how C. elegans neurons control epigenetic inheritance! biorxiv.org/content/10.110…

Kantify (@kantify) 's Twitter Profile Photo

Can an AI for human drug discovery also excel in plant drug discovery? The answer is yes! This is what our COO Nicolas Maignan explained at his lecture "Unlocking & Accelerating Drug Discovery with Artificial Intelligence: The Kantify Approach." held by our partner IBMCP - Instituto de Biología Molecular y Celular 🙏🌿

Can an AI for human drug discovery also excel in plant drug discovery? The answer is yes!
This is what our COO <a href="/Nico_Maignan/">Nicolas Maignan</a> explained at his lecture "Unlocking &amp; Accelerating Drug Discovery with Artificial Intelligence: The Kantify Approach." held by our partner <a href="/IBMCP/">IBMCP - Instituto de Biología Molecular y Celular</a>  🙏🌿
Kantify (@kantify) 's Twitter Profile Photo

Hey Twitter, we are disclosing our biotech pipeline, and there is even a bonus for drug discovery experts. Cancer, Rare Cancers, Rare Neuromuscular disorders, Neurology and Ion Channels are some of our areas of focus.

Felipe MIllon (@felipe_millon) 's Twitter Profile Photo

Today, we at OpenAI launched Deep Researcher and I wanted to share a deeply personal story about how amazing this tool is and how it will change the world. Trigger warning, related to cancer....1/9

Kantify (@kantify) 's Twitter Profile Photo

No! This photo is not AI edited: a heart-shaped sun ray appeared right during our last team photo!❤️ Meet below a team of people working every day with a lot of ❤️, talent, and AI - to accelerate the discovery of therapies for patients who need them the most.

No! This photo is not AI edited: a heart-shaped sun ray appeared right during our last team photo!❤️
Meet below a team of people working every day with a lot of ❤️, talent, and AI - to accelerate the discovery of therapies for patients who need them the most.
Paul Graham (@paulg) 's Twitter Profile Photo

A smart foreign-born undergrad at a US university asked me if he should go to the UK to start his startup because of the random deportations here. I said that while the median startup wasn't taking things to this extreme yet, it would be an advantage in recruiting.

DoctorDueDiligence (@duedoctor) 's Twitter Profile Photo

3. Rare Disease (cited 15 and 72 patients worldwide for example) may get approval based on mechanism of action only - then track and follow patients to see if drug works.

NeurIPS Conference (@neuripsconf) 's Twitter Profile Photo

The NeurIPS 2025 Creative AI Track is now inviting research papers and artworks that explore cutting edge applications of AI and ML in art, design, and creative practice. This year, we welcome submissions on the theme of "Humanity". Read more in our Call for Creative AI 2025:

Zachary Tracer (@ztracer) 's Twitter Profile Photo

ANY foreign clinical trial site that's part of NIH-funded research may be forced to shut down under new 'America First'-driven policy: statnews.com/2025/05/02/nih…

Jason Abaluck (@jabaluck) 's Twitter Profile Photo

Good news everyone! The unpopular and seemingly irrelevant lecture I give in my health econ class on "Most favored nations agreements" just became prophetically relevant. Bad news everyone! This is a terrible policy. 🧵

Eric Topol (@erictopol) 's Twitter Profile Photo

Today "a milestone in the evolution of personalized therapies for rare & ultra-rare inborn errors of metabolism" —the 1st human to undergo custom genome editing —outgrowth of decades of NIH funded research nejm.org/doi/full/10.10… nejm.org/doi/full/10.10… NEJM

Today "a milestone in the evolution of personalized therapies for rare &amp; ultra-rare inborn errors of metabolism"
—the 1st human to undergo custom genome editing
—outgrowth of decades of NIH funded research
nejm.org/doi/full/10.10…
nejm.org/doi/full/10.10… <a href="/NEJM/">NEJM</a>
Hélène Le Borgne (@helenelborgne) 's Twitter Profile Photo

Have your say ! Call for evidence for the Biotech Act: ec.europa.eu/info/law/bette… The biotech sector plays a critical role in several areas of the EU economy. It is research-driven, fast-moving and requires substantial public and private investments.